Johns Hop­kins re­searchers pub­lish a how-to guide­book on Covid-19 plas­ma trans­fu­sions

The nov­el coro­n­avirus’ rapid spread, far out­strip­ping even the ac­cel­er­at­ed time­lines set for new drugs and vac­cines, has sent doc­tors turn­ing to a ther­a­py re­searchers say is promis­ing but which hasn’t been wide­ly used in the US in decades: blood plas­ma do­na­tions from re­cov­er­ing pa­tients.

Yet the nov­el­ty of the pro­ce­dure has left hos­pi­tals fac­ing many ques­tions, rang­ing from how ef­fec­tive the treat­ment is to the ba­sic lo­gis­tics of how to go about get­ting the plas­ma from the arm of a now-healthy per­son and in­to the arm of a still-sick one.

To fill that knowl­edge gap, a team of ex­perts at Johns Hop­kins Med­i­cine has pub­lished a guide­book for con­va­les­cent plas­ma in the Jour­nal of Clin­i­cal On­col­o­gy. Con­tain­ing both step-by-step in­struc­tions for how to han­dle in­fu­sions and an overview of the ev­i­dence sup­port­ing its use, the ar­ti­cle func­tions as both a man­u­al and one of the most sys­tem­at­ic and care­ful Eng­lish lan­guage en­dorse­ments for the use of plas­ma do­na­tions in Covid-19 pa­tients since the out­break be­gan.

Evan Bloch

“We’ve re­ceived many in­quiries from health care providers look­ing to ramp up their abil­i­ty to de­liv­er this ther­a­py,” Evan Bloch, an in­fec­tious dis­ease pro­fes­sor at Hop­kins and lead au­thor, said in a state­ment. “There is his­tor­i­cal prece­dent for its use to pre­vent and treat vi­ral ill­ness. How­ev­er, dur­ing the chaos of an epi­dem­ic, the ther­a­py is of­ten de­ployed with­out rig­or­ous­ly study­ing its ef­fects. Care­ful­ly con­duct­ed stud­ies are crit­i­cal­ly need­ed to un­der­stand which peo­ple are most like­ly to ben­e­fit from this ther­a­py and how best to ap­ply it to op­ti­mize that ben­e­fit.”

The guide­book – which al­so drew from ex­perts at Stan­ford, Co­lum­bia and Wash­ing­ton Uni­ver­si­ty in St. Louis, among oth­ers – ex­plained that al­though da­ta from clin­i­cal tri­als are still need­ed, con­va­les­cent plas­ma has been used as ther­a­py and post-ex­po­sure pro­phy­lax­is for past in­fec­tious dis­eases, in­clud­ing the dead­ly coro­n­avirus­es SARS and MERS, and was used in a lim­it­ed num­ber of Covid-19 cas­es in Chi­na. The ther­a­py works by tak­ing the pas­sive an­ti­bod­ies a pa­tient nat­u­ral­ly gen­er­at­ed in re­sponse to the virus and trans­fer­ring to a new pa­tient, where (hope­ful­ly) it binds to the virus, halt­ing in­fec­tion.

The plas­ma ap­pears to be ef­fec­tive at mul­ti­ple stages but works bet­ter the ear­li­er it is giv­en, the au­thors wrote. They cit­ed a Hong Kong study from the SARS out­break, in which pa­tients giv­en plas­ma in the first 14 days re­cov­ered faster than those giv­en lat­er. Still, a re­port of five crit­i­cal­ly ill Covid-19 pa­tients in Chi­na found that all 5 im­proved af­ter trans­fu­sion, ev­i­dence that “con­va­les­cent plas­ma is safe, re­duces vi­ral load and may im­prove clin­i­cal out­comes.”

“Im­por­tant­ly, pas­sive an­ti­body ad­min­is­tra­tion of­fers the on­ly short-term strat­e­gy to con­fer im­me­di­ate im­mu­ni­ty to sus­cep­ti­ble in­di­vid­u­als,” they wrote. “This is par­tic­u­lar­ly the case in the set­ting of a nov­el, emerg­ing in­fec­tious dis­ease such as SARS- CoV-2/COVID-19.”

By their count, five tri­als have been pro­posed to test the ther­a­py: As post-ex­po­sure pro­phy­lax­is, in mild cas­es, in mod­er­ate cas­es, in chil­dren and as a “res­cue in­ter­ven­tion” for those se­vere­ly ill. The post-ex­po­sure tri­al — a Phase II be­ing run but the Mayo Clin­ic — could give “di­rect clin­i­cal ben­e­fit” for pa­tients while al­so of­fer­ing “wide-rang­ing” so­cial ben­e­fits such as pro­tect­ing health­care work­ers on the front­line. Treat­ing mod­er­ate­ly ill pa­tients might help stave off ven­ti­la­tion and pre­serve the short sup­ply of equip­ment. Crit­i­cal­ly ill pa­tients may be helped by plas­ma, but tri­als on those pa­tients may of­fer lit­tle con­clu­sive da­ta be­cause of “con­found­ing vari­ables,” in­clud­ing oth­er ex­per­i­men­tal ther­a­pies, the au­thors con­clud­ed.

There’s still much we don’t know about plas­ma trans­fu­sions and an­ti­bod­ies to Covid-19, they ac­knowl­edged. That in­cludes which of the an­ti­bod­ies the body makes best to neu­tral­ize the virus, and though you can screen blood for dif­fer­ent an­ti­bod­ies, it takes time. Their re­view of the lab da­ta in­di­cat­ed most pa­tients would have enough an­ti­bod­ies for do­na­tion 14 days af­ter their symp­toms end­ed.

For eq­ui­table ac­cess to plas­ma, they rec­om­mend­ed donors be screened in a clin­ic for both the virus and its an­ti­bod­ies. If the for­mer’s neg­a­tive and the lat­ter pos­i­tive, they are then di­rect­ed to do­nate at a blood cen­ter, which then shares it with hos­pi­tals, who dis­trib­ute it ac­cord­ing to those in clin­i­cal tri­als or with emer­gency use au­tho­riza­tions. They ar­gued risks — ei­ther from con­tract­ing an in­fec­tion from the donor or from a phe­nom­e­na called an­ti­body-de­pen­dent en­hance­ment, where mon­o­clon­al an­ti­bod­ies can wors­en the dis­ease — were low, but cau­tioned time and da­ta were need­ed.

“The risks of COVID-19 in­fec­tion are pro­found,” they con­clud­ed. “Hu­man plas­ma from re­cov­ered COVID-19 pa­tients is pro­ject­ed to be a safe and po­ten­tial­ly ef­fec­tive ther­a­py for treat­ment and post-ex­po­sure pro­phy­lax­is alike. Sub­stan­tial ev­i­dence of ben­e­fit with pri­or use for vi­ral in­fec­tions of­fers strong prece­dent for such an ap­proach. How­ev­er, it is crit­i­cal­ly im­por­tant to per­form well con­trolled clin­i­cal tri­als to con­firm ef­fi­ca­cy, there­by in­form­ing ra­tio­nal ev­i­dence-based de­ci­sion-mak­ing.”

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.

Inside FDA HQ (File photo)

The FDA just ap­proved the third Duchenne MD drug. And reg­u­la­tors still don’t know if any of them work

Last year Sarepta hit center stage with the FDA’s controversial reversal of its CRL for the company’s second Duchenne muscular dystrophy drug — after the biotech was ambushed by agency insiders ready to reject a second pitch based on the same disease biomarker used for the first approval for eteplirsen, without actual data on the efficacy of the drug.

On Wednesday the FDA approved the third Duchenne MD drug, based on the same biomarker. And regulators were ready to act yet again despite the lack of efficacy data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Franz-Werner Haas, CureVac CEO

UP­DAT­ED: On the heels of a snap $1B raise, Cure­Vac out­lines plans to seek emer­gency OK for Covid-19 vac­cine -- shares rock­et up

CureVac is going from being one of the quietest players in the race to develop a new vaccine to fight the worst public health crisis in a century to a challenger for the multibillion-dollar market that awaits the first vaccines to make it over the finish line. Typically low-key at a time of brash comments and incredibly ambitious development timelines from the leaders, CureVac now is jumping straight into the spotlight.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

FDA ap­proves the third NSOMD drug in 18 months as Roche/Genen­tech beefs up its port­fo­lio of drugs for neu­ro­log­i­cal dis­or­ders

There were no FDA approved treatments for neuromyelitis optica spectrum disorder at the start of 2019. Now, as of Friday, there are three.

The latest entrant to the market is the Roche/Genentech drug satralizumab after US regulators gave it the thumbs up late Friday. An IL-6 inhibitor, the drug joins Alexion’s Soliris and AstraZeneca spinout Viela Bio’s Uplizna. The annual cost of satralizumab — which will hit the market as Enspryng — will be $190,000 for 13 doses, a Genentech spokesperson said, though the first year of treatment requires 15 doses and cost about $220,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Stéphane Bancel speaks to President Donald Trump at the White House meeting on March 2 (AP Images)

UP­DAT­ED: Mod­er­na of­fers steep dis­count in US sup­ply deal — but still takes the crown with close to $2.5B in vac­cine con­tracts

The US pre-order for Moderna’s Covid-19 vaccine is in.

Operation Warp Speed is reserving $1.525 billion for 100 million doses of Moderna’s Phase III mRNA candidate, rounding out to about $15 per dose — including $300 million in incentive payments for timely delivery. Given that Moderna has a two-dose regimen, it’s good for vaccinating 50 million people. The US government also has the option to purchase another 400 million doses for a total of $6.6 billion, or $16.5 per dose.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

Controversial human challenge trials for potential Covid-19 vaccines reportedly have a new booster — the US government.

Scientists working for the government have begun manufacturing a strain of the novel coronavirus that could be used in such studies, Reuters reported Friday morning. The trials would enroll healthy volunteers to be vaccinated and then intentionally infected with a weakened coronavirus.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. (Virginia Mayo/AP Images)

UP­DAT­ED: End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

(This piece was last updated on August 14. Endpoints News will continue to track the latest developments through the FDA’s marketing decisions.)

The 28 players now in or close to the clinical race to get a Covid-19 vaccine over the finish line are angling for a piece of a multibillion-dollar market. And being first — or among the leaders — will play a big role in determining just how big a piece.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Sanofi vet Kather­ine Bowdish named CEO of PIC Ther­a­peu­tics; As the world Terns: Liv­er dis­ease biotech makes ex­ec­u­tive changes

PIC Therapeutics hasn’t raised much money, yet. But the fledgling biotech has attracted a high-profile player to the helm.

The Boston-based biotech has handed the reins to Katherine Bowdish as its president and CEO. Bowdish will also join the board of directors of PIC. Bowdish joins from Sanofi where she served as VP and head of R&D strategy, as well as helping launch and lead Sanofi Sunrise, a venture investment and partnering vehicle at Sanofi. Before that, Bowdish held several exec roles at Permeon Biologics, Anaphore, Alexion Pharmaceuticals and Prolifaron (acquired by Alexion).

NIH director Francis Collins at a Senate Appropriations subcommittee hearing for Operation Warp Speed (Graeme Jennings/Pool via AP Images)

Covid-19 roundup: As­traZeneca signs 400M vac­cine sup­ply deal with EU; Sinopharm re­ports pos­i­tive Phase I/II da­ta for vac­cine can­di­date

Amid talks with multiple players, the European Commission has reached its first vaccine supply deal with AstraZeneca, securing 400 million doses of the Oxford candidate for all of its member countries.

The pharma giant said in a press release that the deal builds on the existing agreement with Germany, France, Italy and the Netherlands, announced in June. It was unclear, however, whether that means simply extending the same 400 million doses to all EU countries or doubling the reservation to 800 million doses.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Bayer's Marianne De Backer with Endpoints founder John Carroll, Endpoints@JPM20 (Jeff Rumans for Endpoints News)

Hunt­ing a block­buster, Bay­er forges an $875M-plus M&A deal to ac­quire women’s health biotech

Bayer has dropped $425 million in cash on its latest women’s health bet, bringing a UK biotech and its non-hormonal menopause treatment into the fold.

KaNDy Therapeutics had its roots in GlaxoSmithKline, which spun out several neuroscience drugs into NeRRe Therapeutics back in 2012. Five years later the team created a new biotech to focus solely on NT-814 — which they considered “one of the few true innovations in women’s health in more than two decades.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.